Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
06:30am, Thursday, 10'th Oct 2024
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Approaching A Moment Of Truth With Zanidatamab
02:47pm, Friday, 27'th Sep 2024
ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indicati
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
06:00am, Wednesday, 18'th Sep 2024
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms Presentations to highlight progress i
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
04:30pm, Tuesday, 03'rd Sep 2024
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks Announces Participation in Upcoming Investor Conferences
06:30am, Thursday, 22'nd Aug 2024
VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
10:58pm, Thursday, 01'st Aug 2024
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Bijal Desai - Vice President-Finance & Stra
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
07:11pm, Thursday, 01'st Aug 2024
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.76 per share a year ago.
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
04:10pm, Thursday, 01'st Aug 2024
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 Zymeworks intends to comm
Zymeworks Announces Participation in Upcoming Investor Conferences
06:30am, Tuesday, 30'th Jul 2024
VANCOUVER, British Columbia, July 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
04:30pm, Thursday, 25'th Jul 2024
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
06:30am, Thursday, 11'th Jul 2024
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
VANCOUVER, British Columbia, June 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME
07:30am, Friday, 31'st May 2024
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of fe
